Belzutifan recently received FDA approval to treat adult patients with pancreatic neuroendocrine tumors, central nervous system hemangioblastomas, and VHL-associated ccRCC [151]. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.